Member Info for EyeGuy

15% up

Should do 30% today imo. £1 coming imo

Let’s not forget guys- it went up 33% AGAINST A $10 MILLION FUNDRAISE. 60x average volume. Immense interest. 3-5 bagger coming imo

biggest riser tomorrow by far. And lets not forget they are up 30% on the back of a placing. wow

should be a good ride up now.

personally think the treatment phase will be a key market over next year. And TILS have already stated that they have key advantages over competitors. Should be seriously multi bagging

will move sharply over next few weeks imo. Certainly we are moving on to the treatment phase.

MAJOR ADVANTAGE FOR TREATING COVID 19!!
About TZLS-501
TZLS-501, a fully human mAb, was acquired from Novimmune, SA, a Swiss biotechnology company, in 2017. The cytokine, IL-6, a major determinant in the priming of pathogenic T cells to produce an inflammatory response, binds to its receptor subunit IL-6Ra on the cell membrane. The receptor IL-6Ra can be shed in soluble form, sIL6Ra, which binds to circulating IL-6 cytokine in the blood. The downstream signaling from this complex mediates pro-inflammatory effects underlying inflammatory diseases such as rheumatoid arthritis (RA) and acute respiratory distress syndrome (ARDS). The Company believes that the features of TZLS-501 consisting of its dual mechanism of action to inhibit signaling by the membrane-bound and soluble IL-6 receptor and the rapid depletion of circulating IL-6 cytokines, a major cause of lung damage, provides TZLS-501 with distinct advantages for treatment of COVID-19.

yep. load up when cheap. USA open soon. should be at £2 soon imo

hold for a mulitbagger imo

"We believe that the features of TZLS-501 consisting of its dual mechanism of action to inhibit signaling by the membrane-bound and soluble IL-6 receptors along with rapid depletion of circulating IL-6 cytokine, a major cause of lung damage, provides TZLS-501 with distinct advantages for treatment of COVID-19 over other anti-IL-6R mAbs such as Actemra® and Kevzara® for treatment of COVID-19. The recent decision by researchers in China to add Actemra® to treatment guidelines for coronavirus patients with serious lung damage confirms the utility of anti-IL6R mAb. We are excited to move forward with our clinical development plan to expedite evaluation in patients as soon as possible", said Dr. Kunwar Shailubhai, CEO & CSO of Tiziana Life Sciences.

This drug can treat and has advantages over other drugs. Could be worth billions

This is going to be a hot stock. Americans will buy into this heavily and this should be a real mover over next week or so. Could be ££££

added some. Don't forget this is NASDAQ listed and could well go nuts for a while yet dragging us along.

possibly both. markets are terrible but will gladly add down here.

very happy to accumulate shares here. anything around 0.10p is a bargain imo

Suhail- most placings at these levels done with bucket shops. and the people that took part in the placing unlikely to sell at a loss and note they still took it when the bid was 0.07. tells me they expect a good rise
that's out of the way now.
onwards and upwards.
no idea why you have turned. the asset is a world class gas asset.

Looking forward to a good rise now ;-)

Suhail - you have changed your tune. Guessing you sold. But you were valuing the gas at £300 million.
Only difference is now more shares in issue and they have cash to progress.
See you at 0.3p

And also if the placing was pulled the company would be in trouble. It wasn’t pulled so onwards and upwards now